Meeting
2013 ASCO Annual Meeting
Preclinical studies with neratinib in triple-negative breast cancer.
Authors
Maeve Mullooly
Education and Research Centre, St.Vincent's University Hospital and School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
Maeve Mullooly , Neil A. O'Brien , Dylan Conklin , Richard S. Finn , Dennis J. Slamon , John Crown , Norma O'Donovan , Patricia M. McGowan , Michael J. Duffy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 1054)
DOI
10.1200/jco.2013.31.15_suppl.1054
Abstract #
1054
Poster Bd #
20E
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Distinct mutational landscape between HR+ and HR- HER2+ early-stage breast cancer patients.
First Author: Bo Chen
Poster
2019 ASCO Annual Meeting
Actionable coalterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
First Author: Arielle Lutterman Heeke
Poster
2018 ASCO Annual Meeting
Phase I study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplification, HER2 mutation/amplification or HER3/4 mutation.
First Author: Sarina Anne Piha-Paul
Poster
2017 ASCO Annual Meeting
Individualized screening trial of innovative glioblastoma therapy (INSIGhT).
First Author: Brian Michael Alexander